Clinical Outcomes Of A New Monofocal Intraocular Lens In Patients With Pre- Existing Comorbidities

To assess and report on the safety and efficacy of the new TECNIS Eyhance monofocal intraocular lens in patients with pre-existing comorbidities.

Private Refractive Surgery (Optical Express)

141 patients, 267 eyes, with pre-existing comorbidities, who underwent cataract surgery or refractive lens exchange with unilateral or bilateral implantation of the TECNIS Eyhance ICB00 were retrospectively reviewed. The following comorbidities were included: lazy eye, squint, macular degeneration, retinal problems, ocular hypertension, glaucoma, and keratoconus. The age range of patients was 39 to 80 years. Postoperative clinical safety, efficacy, and patient-reported outcomes up to 12 months following implant were analysed.

Mean gain in visual acuity lines for uncorrected distance, intermediate, and near was 8, 4, and 4, respectively. One patient lost more than 2 lines of BCDVA, while 83% were ±1 line from preoperative BCVA. The rate of postoperative adverse events related to the IOL remains low and is comparable to patients with no pre-existing comorbidities who were implanted with the Eyhance lens. No patients reported experiencing severe difficulty with glare, halo or starbursts. 87% of patients reported being satisfied or very satisfied, while 90% would recommend the procedure to friends and family.

Outcomes of this retrospective analysis suggest the new Eyhance monofocal intraocular lens is a safe and efficacious option for patients with pre- existing comorbidities. Thus far, the IOL showed low incidence of visual phenomena and complications within the first year. A larger data sample with longer follow-up is warranted to confirm.